Neurocrine Biosciences (NBIX) EV to CFO (2010 - 2026)
Neurocrine Biosciences' (NBIX) EV to CFO stood at 12.79 in Q3 2026, down 36.8% from 20.23 a year earlier and down 31.4% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EV to CFO (2010 - 2026) Analysis & Trends
On a TTM basis, Neurocrine Biosciences' EV to CFO came in at 9.80 as of Sep 30, 2026, down 36.9% year-over-year; for FY2025, it was 16.25, down 22.6% from FY2024.
- Annual EV to CFO has declined for three straight years.
- Across earlier years, EV to CFO came in at 20.98 in FY2024 (-31.6%), 30.69 in FY2023 (-1.1%), 31.02 in FY2022 (+8.0%) and 28.73 in FY2021 (-19.5%).
- The Q3 2026 figure is the lowest quarterly EV to CFO in data going back to Q2 2018.
- On a year-over-year basis, EV to CFO has declined for 15 consecutive quarters, with an average decline of 19.2% over the last eight quarters.
- Peak year-over-year performance for EV to CFO in the last five years was growth of 117.1% in Q1 2022, against a decline of 48.2% in Q3 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at 18.63 (Q2 2026), 13.82 (Q1 2026) and 16.25 (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 12.79 |
| Jun 30, 2026 | 18.63 |
| Mar 31, 2026 | 13.82 |
| Dec 31, 2025 | 16.25 |
| Sep 30, 2025 | 20.23 |
| Jun 30, 2025 | 20.21 |
| Mar 31, 2025 | 18.88 |
| Dec 31, 2024 | 20.98 |
| Sep 30, 2024 | 21.90 |
| Jun 30, 2024 | 24.23 |
| Mar 31, 2024 | 19.62 |
| Dec 31, 2023 | 30.69 |
| Sep 30, 2023 | 24.31 |
| Jun 30, 2023 | 27.78 |
| Mar 31, 2023 | 35.23 |
| Dec 31, 2022 | 31.02 |
| Sep 30, 2022 | 46.90 |
| Jun 30, 2022 | 53.00 |
| Mar 31, 2022 | 64.40 |
| Dec 31, 2021 | 28.73 |
API Access
Neurocrine Biosciences EV to CFO API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-cfo", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();